SNP-162

SNP-162 is a preclinical **small-molecule kinase inhibitor** being developed by Snap Bio for liver cancer, particularly recurrent, advanced, metastatic, and sorafenib-resistant disease. Publicly available information indicates that the program was positioned as a potentially first-in-class targeted therapy with activity in hepatocellular carcinoma and possibly hepatoblastoma models, but the precise molecular target or kinase target set has not been clearly disclosed in reliable public sources. Available descriptions emphasize potent inhibition of sorafenib-resistant liver cancer cell growth and high kinase selectivity, with development remaining in the preclinical stage.